In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Caitlin M O'SheaSchool of Life Sciences, University of Essex, Colchester, United Kingdom.
Rushba ShahzadSchool of Life Sciences, University of Essex, Colchester, United Kingdom.
Kimia AghasoleimaniSchool of Life Sciences, University of Essex, Colchester, United Kingdom.
Stuart NewmanSchool of Life Sciences, University of Essex, Colchester, United Kingdom.
Jiraporn PanmaneeResearch Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
Fiona E BensonDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom.
James S TrimmerUC Davis/NIH NeuroMab Facility, Department of Physiology and Membrane Biology, University of California School of Medicine, Davis, CA, USA.ORCID 0000-0002-6117-3912 Takao FujisawaLaboratory of Cell Signalling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID 0000-0001-7401-5457 Hidenori IchijoLaboratory of Cell Signalling, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID 0000-0002-5005-6438 Neil R CashmanDjavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-0080-1006 Stanislav EngelDepartment of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.ORCID 0000-0001-5916-5190 Gareth S A WrightSchool of Life Sciences, University of Essex, Colchester, United Kingdom. gareth.wright@essex.ac.uk.ORCID 0000-0002-3756-9634 Funding
Recombinant Immunolabels for Nanoprecise Brain Mapping Across ScalesU24NS109113 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KARL Daniel MURRAY · 2018 to 2026
$9.9MNABOR: A Sustainable, High-quality Neuroscience Antibody Open ResourceU24NS119916 · NINDS · ADDGENE, INC. · PI FAN, MELINA · 2021 to 2023
$4.2MAcademy of Medical Sciences SBF008\1028Israel Science Foundation (ISF) 221/22Japan Agency for Medical Research and Development (AMED) 22gm0010009s0101Japan Agency for Medical Research and Development (AMED) 23gm0010009s0102Japan Agency for Medical Research and Development (AMED) 23gm1710001s0102Japan Agency for Medical Research and Development (AMED) JP21gm5010001Japan Society for the Promotion of Science London (JSPS London) 25H00971MEXT | Japan Science and Technology Agency (JST) JPMJMS2022-18Motor Neurone Disease Association (MNDA) Wright/Apr25/2472-791Motor Neurone Disease Association (MNDA) Wright/Oct18/969-799National Research Council of Thailand (NRCT) N42A67012NINDS NIH HHS U24 NS109113NINDS NIH HHS U24 NS119916Royal Society RGS\R1\231005
6 · The paper itselfAbstract
Eighty-five percent of the human proteome has at least one interacting monoclonal antibody. These molecules penetrate the cytoplasm poorly and are very often non-functional within the cell. Analysis of antibody variable domains and characterisation of forty-five single-chain variable fragment (scFv) intrabodies expressed in human cells indicated charge to have the greatest impact on solubility. We created new interdomain linkers, optimised scFv domain orientation and found an optimisable charge discrepancy between variable heavy framework and CDR sites. When applied to reduce the search space and rank the products of AI-led inverse folding this creates a single highly soluble, abundant and stable intrabody with parent antibody epitope recognition. Over six hundred intrabody sequences are presented targeting sixty cytoplasmic proteins with linear, conformational, post-translational modification or oligomer specificity. Interactions were validated for p53, α-synuclein, SOD1, polyQ, FUS/TLS, UCHL1 and GFP. Here we show reliable repurposing of the sequenced antibody interactome inside the cell.
Indexed as
Antibodies, MonoclonalSingle-Chain Antibodiesalpha-SynucleinAmino Acid SequenceEpitopesHumansProteomeTumor Suppressor Protein p53alpha-SynucleinAntibodies, MonoclonalEpitopesProteomeSingle-Chain AntibodiesTumor Suppressor Protein p53
Identifiers
PMID41620420
PMCPMC12963631
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390